News
Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...
Hosted on MSN1mon
Camurus, Eli Lilly Collaborate for Long-Acting Incretin Products Using FluidCrystal Technology - MSNCamurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops ...
Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX.
Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal ® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million ...
Camurus AB Annual stock financials by MarketWatch. View the latest CAMX financial statements, income statements and financial ratios.
Camurus AB (STO:CAMX) presented its first quarter 2025 results on May 15, revealing strong financial performance despite challenging market conditions. The Swedish biopharmaceutical company, which ...
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe ...
Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX.
Camurus’ Oczyesa receives European marketing authorization for treatment of acromegaly: Lund, Sweden Wednesday, July 2, 2025, 17:00 Hrs [IST] Camurus, an international, science- ...
Camurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops ...
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results